Tracking the spread of drug-resistant bacteria in households

Household Transmission Dynamics of Multidrug Resistant Enterobacterales

Observational Assistance Publique - Hôpitaux de Paris · NCT05798364

This study looks at how often drug-resistant bacteria spreads from hospital patients to their family members at home over three months.

Quick facts

Study typeObservational
Enrollment507 (estimated)
SexAll
SponsorAssistance Publique - Hôpitaux de Paris Academic / other
Locations1 site (Paris, Île-de-France Region)
Trial IDNCT05798364 on ClinicalTrials.gov

What this trial studies

This observational study will follow adults who are carriers of Multi-Drug Resistant Enterobacterales (MDR-E) after they leave the hospital, along with their household members, over a three-month period. The main goal is to estimate how often MDR-E is transmitted from the index patient to others in the household, confirmed through genomic analysis of bacterial strains. The study will also explore various factors that may influence transmission dynamics and will use modeling to simulate control strategies for reducing the spread of these bacteria in the community.

Who should consider this trial

Good fit: Ideal candidates include adults who have been hospitalized and are positive for MDR-E fecal carriage, living with at least two household members who agree to participate.

Not a fit: Patients who do not live with other household members or those who have had documented MDR-E fecal carriage in the past year may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved strategies for controlling the spread of drug-resistant infections in households.

How similar studies have performed: While there is limited research on household transmission dynamics of MDR-E, the approach of using genomic analysis to confirm transmission is innovative and has not been widely tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion criteria :

Index patients

* adults (≥ 18 years)
* hospitalized in participating hospitals
* positive for MDR-E fecal carriage on routine screening during hospital stay
* with no documented MDR-E fecal carriage in the 12 months preceding current hospitalization
* regularly living with at least two additional household members who expressed their non-opposition to participate.
* planning to live in Ile de France for the next three months Household members
* adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion, and who expressed their non-opposition to participate.
* planning to live in Ile de France for the next three months

Exclusion criteria :

Lack of non-opposition to participate and to use clinical data

* Subject under legal protection (guardianship)
* Subject deprived of liberty under judicial constraint
* Subject undergoing psychiatric care
* Lack of affiliation to a social security scheme Secondary exclusion criteria
* Index member negative for MDR-E fecal carriage either before discharge (D-7 to D-2) or on day of discharge (D0)."

Where this trial is running

Paris, Île-de-France Region

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Adults Patients, With Fecal Carriage of Multi-Drug Resistant EnterobacteralesMulti-Drug Resistant EnterobacteralesExtended-Spectrum Beta-Lactamase producing EnterobacteralesCarbapenemase-Producing EnterobacteralesTransmissionCommunityhouseholdsMathematical modelling
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.